基础血脂水平对HMG-CoA还原酶抑制剂降脂作用的影响  

Relation between baseline lipid levels and effectiveness of HMG-CoA reductase inhibitors in patients with hyperlipidemia

作　　者：伍卫[1] 周淑娴[1] 韦育林[1] 张燕[1] 王景峰[1] 张旭明[1] 

机构地区：[1]中山医科大学孙逸仙纪念医院心内科,广州市510120

出　　处：《岭南心血管病杂志》2001年第2期110-113,共4页South China Journal of Cardiovascular Diseases

摘　　要：目的　观察治疗前基础血脂水平对HMG CoA还原酶抑制剂降低血清总胆固醇 (TC)、低密度脂蛋白胆固醇(LDL C)以及血清甘油三酯 (TG)作用的影响。方法　分析1994～ 1999年期间进行的 3项多中心临床药物试验 :辛伐他汀试验 (16 6例 ,平均年龄 5 8 9岁± 9 2岁 ) ,洛伐他汀试验(146例 ,平均年龄 5 7 9岁± 8 7岁 ) ,阿伐他汀试验 (10 5例 ,平均年龄 5 7 8岁± 9 3岁 )。治疗前血清TC≥ 5 98mmol·L-1,血清TG≤ 4 5 2mmol·L-1。按治疗前基础血脂水平分组。分别口服辛伐他汀 10mg·d-1,疗程 8周 ;或洛伐他汀2 0mg·d-1,疗程 8周 ;或阿伐他汀 10mg·d-1,疗程 6周。结果　治疗前基础血清TC、LDL C以及TG水平越高 ,HMG CoA还原酶抑制剂降低相应血脂的作用越明显。辛伐他汀、洛伐他汀或阿伐他汀降低血清TC、LDL C以及TG的幅度分别与治疗前相应的基础血脂水平呈正相关。结论　HMGObjective To evaluate whether the effects of HMG CoA reductase inhibitors on patients with hyperlipidemia are closely related to baseline lipid levels. Methods The data analyzed were originated from 3 separate multicenter clinical trials with similar designs during 1994 to 1999. 166 patients with mean age (58 9±9 2) years were involved in Simvastatin Clinical Trial with simvastatin 10 mg once daily for 8 weeks. 146 patients with mean age (57 9±8 7) years were involved in Lovastatin Clinical Trial with lovastatin 20 mg once daily for 8 weeks. 105 patients with mean age (57 8±9 3) years were involved in Atorvastatin Clinical Trial with atorvastatin 10 mg once daily for 6 weeks. Baseline total cholesterol (TC) was more than 5 98mmol·L -1 , and baseline triglyceride(TG) was less than 4 52 mmol·L -1 . The patients were grouped by baseline lipid levels.Results The higher the baseline TC, low density lipoprotein cholesterol (LDL C) and TG levels were, the more effective the simvastatin, lovastatin, or atorvastatin was in reducing serum TC, LDL C, and TG, respectively. A positive linear correlation was found between baseline values and effects of simvastatin, lovastatin, or atorvastatin in reducing serum TC, LDL C, and TG, respectively.Conclusion The changes of reduction on serum lipid with HMG CoA reductase inhibitors in patients with hyperlipidemia were influenced by baseline lipid levels.

关 键 词：HMG-COA还原酶抑制剂 基础血脂水平 治疗作用 药理 

分 类 号：R972.6[医药卫生—药品]